Difference between revisions of "Abemaciclib (Verzenio)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
m (Jwarner moved page Abemaciclib (LY2835219) to Abemaciclib (Verzenio): FDA approval) |
(No difference)
| |
Revision as of 19:48, 28 September 2017
Mechanism of action
From NCI Drug Dictionary: An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1.
Preliminary data
Breast cancer
- MONARCH 2 (to be added)